A randomized placebo-controlled trial was conducted to determine the benefit of ganciclovir (5 mg/ [kgrd]) for 30 days in addition to intravenous immune globulin (IVIG) for 16 weeks for prevention of primary cytomegalovirus (CMV) disease in children receiving liver transplants. Patients were monitored for 6 months after transplantation. The two groups of patients (recipients of 29 ganciclovir plus IVIG and 27 recipients of IVIG alone) were similar in terms of age, sex, and underlying disease. The incidence of CMV disease among the ganciclovir plus IVIG recipients and the IVIG alone recipients was 17% and 26%, respectively, and the time to disease in these recipients was 46 days and 32 days, respectively. There was no difference between groups in terms of survival; episodes of rejection, bacteremia, or fungemia; use of immunosuppressive agents; and incidence of leukopenia or thrombocytopenia. These results suggest that a 4-week course of ganciclovir with IVIG is not more effective than IVIG alone for prevention of primary CMV disease. Since short-term prophylaxis with ganciclovir may delay the onset of CMV disease, further studies with a longer course of ganciclovir prophylaxis are warranted.
In children, as in adults, cytomegalovirus (CMV) has been tive, randomized, controlled trials evaluating these strategies have enrolled mostly adult transplant recipients, with only a a major cause of morbidity after solid-organ transplantation [1 -5] . Infected patients may develop symptomatic CMV disfew transplant recipients at risk for primary infection (CMVseropositive donor/CMV-seronegative recipient) [10 -17] . ease with pneumonia, hepatitis, gastrointestinal ulcers, retinitis, or a viral syndrome with persistent fever, neutropenia, and None of these prophylactic strategies have been demonstrated to be consistently effective in prevention of primary CMV thrombocytopenia. CMV infection has also been associated with an increased risk of both fungal infections [5, 6] and disease. However, a meta-analysis of randomized, controlled trials of immune globulin as prophylaxis for CMV disease in bacterial infections [7, 8] as well as with allograft injury [1] . The major factors contributing to the risk of severe CMV distransplant recipients found a significant beneficial effect with a common odds ratio of 0.58 [18] . In this analysis, the common ease are donor/recipient serostatus and the use of monoclonal antibodies to T cells (OKT3) or antilymphocyte products [9] .
odds ratio for a CMV-seropositive donor/CMV-seronegative recipient was 0.46 (95% CI, 0.24 -0.81). Therefore, in many CMV-seronegative recipients of transplants from CMV-seropositive donors develop primary CMV disease that is associated pediatric transplant programs, immune globulin prophylaxis was given to CMV-seronegative recipients of transplants from with high morbidity and mortality [1 -5] .
Prophylactic strategies for CMV disease have included use CMV-seropositive donors. We hypothesized that a combination strategy consisting of of CMV-seronegative blood products, intravenous immune globulin (IVIG), high-dose acyclovir, and ganciclovir. Prospecboth passive immunization and antiviral chemotherapy would be more effective than passive immunization alone in this group of transplant recipients at risk of primary CMV disease. The objective of this randomized study was to assess the effective-and the United States were enrolled in the study if they met infiltrates on the chest roentgenogram and if CMV was recovered from a bronchoalveolar lavage fluid or lung biopsy specithe following criteria: age younger than 18 years, CMV-seronegative recipient, and CMV-seropositive donor. The donor's men (as defined above). CMV viral syndrome was defined as persistent fever with neutropenia or thrombocytopenia in a CMV serostatus was determined by latex agglutination (CMV SCAN, Becton Dickinson Microbiology Systems, Cockeyspatient with CMV infection (as defined above) and no other attributable cause. ville, MD). The recipient's CMV serostatus was measured by commercial assays with use of either latex agglutination or ELISA [18] . Informed consent was obtained for each patient.
Laboratory Procedures

Study Drugs
Patients were followed up for 6 months after transplantation. Throat, urine, and buffy coat specimens for viral cultures were Patients were assigned consecutively at each center to reobtained at entry into the study, weekly from weeks 1 to 8, ceive either ganciclovir or placebo (saline) intravenously for biweekly from weeks 10 to 16, and at week 24. Whenever 30 days after transplantation. Randomization was stratified by appropriate, viral cultures of lesions, bronchoalveolar lavage center by means of block randomization with blocks of variable fluid, biopsy tissue, and autopsy tissue specimens were persize. Assignment was double blind. Ganciclovir (5 mg/[kgrd])
formed. Bronchoalveolar lavage fluid and tissue specimens was given once daily. The dose of ganciclovir was modified for were also examined histologically. Complete blood counts and renal function according to guidelines from the manufacturer assays for serum creatinine levels, electrolyte levels, and liver (Syntex, Palo Alto, CA). Ganciclovir administration was interfunction were done before and during the study to assess for rupted if the absolute neutrophil count (ANC) fell to õ500/ treatment-related side effects. Liver biopsy specimens were mm 3 and was reinstituted when the ANC rose to §750/mm 3 . graded histologically for rejection. Ganciclovir administration also was interrupted if the platelet count fell to õ25,000/mm 3 and was reinstituted when the platelet count rose to §50,000/mm 3 .
Transplant Procedures
All patients, both those receiving ganciclovir and those receiving placebo, were given infusions with IVIG (Gammagard, In this multicenter study, patients were treated according to Hyland Division, Baxter Healthcare Corporation, Glendale, standard practice at their transplantation centers. Acyclovir was CA) in the following schedule after transplantation: 1 g/kg not used as prophylaxis for CMV disease or herpes simplex. within 72 hours and then 500 mg/kg weekly for weeks 1 to 8
Acyclovir was used as treatment of symptoms or signs consisand biweekly for weeks 10 to 16 . tent with herpes simplex or varicella. The use of blood products If a patient developed CMV disease, the primary physician screened as CMV-seronegative was standard practice in all could discontinue administration of the study drug and start transplantation centers. treatment with ganciclovir.
CMV Infection Study Approval
CMV infection was defined as isolation of CMV from a The protocol was approved by the human subjects review specimen obtained from any site or as histological evidence of committee at each participating center. In addition, since at the CMV in a tissue specimen, as indicated by the presence of time of starting the study ganciclovir was not licensed for use cytomegalic cells with nuclear inclusions or CMV DNA by in in either the United States or Canada and IVIG was not licensed situ hybridization [19] . The shell vial technique with use of for use in Canada, the protocol was reviewed and approved by monoclonal antibody was used for detection of CMV in the the U.S. Food and Drug Administration and the Health Protecbuffy coat of the blood and in other specimens. Seroconversion tion Branch of Canada. was not used to diagnose infection because of administration of IVIG.
Safety Committee
CMV Disease
The safety committee was independent of the study investigators and consisted of members with differing areas of exper-CMV hepatitis was defined as clinical evidence of hepatitis and biopsy-proven tissue invasion by CMV. CMV gastrointestise, including infectious diseases, transplant medicine, and biostatistics. This committee reviewed the events of the study on tinal disease was defined as biopsy-proven tissue invasion by CMV along with gastrointestinal symptoms not explainable by an ongoing basis. The committee knew the group to which a subject had been assigned but were not aware of which interother causes. CMV pneumonia was diagnosed if there were symptoms and signs of pneumonia and interstitial pulmonary vention had been assigned to each group.
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Statistical Analysis
patients were similar in terms of age, sex, underlying disease, immunosuppressive agents, and rejection episodes (table 1). Fisher's exact test was used to compare differences in pro-
The incidence of CMV disease and infection in the two study portions, and Student's t-test was used to compare means. The groups is shown in figure 1 . By 6 months after transplantation, comparison of times to events was performed by the Kaplan-CMV disease had developed in five (17%) of the 29 ganciclovir Meier method and was analyzed by the logrank test [20] . A sample size of 42 per group would have given an 80% power for the primary outcome of incidence of CMV disease to detect a 50% reduction in the baseline event rate of 60% at a .05 level of significance.
Results
Enrollment was stopped early because by January 1995, the treating physicians wanted to give antiviral drugs as prophylaxis or preemptive therapy for CMV disease in this population. Sixty-two patients were enrolled from six centers (median, eight patients per center; range, four to 21 patients per center). Six were excluded within 72 hours of enrollment because of the following reasons: two were seropositive recipients, one episodes, respectively, for the IVIG alone group (P Å .18 and * Disease was diagnosed after CMV hepatitis was diagnosed.
P Å .76, respectively). The groups did not differ in terms of the number of episodes of rejection or the immunosuppressive agents used (table 1) . plus IVIG recipients and seven (26%) of the 27 IVIG alone
The mean WBC counts were similar for both groups throughout recipients (logrank x 2 test; P Å .4208) (table 2). All IVIG the study period, including the 30 days of ganciclovir adminisrecipients with CMV disease had onset of the disease before tration (figure 2). The number of episodes of neutropenia 8 weeks after transplantation, whereas only two of five gan-(ANC, õ1,000/mm 3 ) was similar in the two groups, as was ciclovir plus IVIG recipients with CMV disease had onset in the number of episodes of thrombocytopenia (platelet count, the first 8 weeks after transplant. The mean time to onset of õ100,000/mm 3 ). One patient in the ganciclovir plus IVIG CMV disease was 46 days for the ganciclovir plus IVIG group group and seven in the IVIG alone group had episodes of and 32 days for the IVIG alone group (P Å .36).
neutropenia. There were 27 and 25 episodes of severe thromboBy 6 months after transplantation, CMV infection had been cytopenia (platelet count, õ20,000/mm 3 ) in the ganciclovir detected in 16 (55%) of the 29 ganciclovir plus IVIG recipients plus IVIG and IVIG alone groups, respectively. and 11 (41%) of the 27 IVIG alone recipients (logrank x 2 test; Seven patients in the ganciclovir plus IVIG group and four P Å .4877). Viremia occurred in five ganciclovir plus IVIG in the IVIG alone group were treated with acyclovir. The durarecipients (17%) and five IVIG alone recipients (19%). Twelve tions of acyclovir use in these two groups were 24 and 39 days, patients in the ganciclovir plus IVIG group and 10 in the IVIG respectively. The mean day of starting acyclovir therapy was alone group were treated for confirmed or suspected CMV day 39 for the ganciclovir plus IVIG group and day 17 for the disease. Confirmed CMV disease was as defined under Meth-IVIG alone group. None of these differences was statistically ods. CMV disease was suspected during episodes of CMV significant. The outcomes of CMV disease and infection and viremia when there was clinical evidence of CMV disease before a tissue sample or bronchoalveolar lavage fluid specimen had been obtained. For treatment of CMV disease, the dosage of ganciclovir was increased to 10 mg/(kgrd) in two divided doses for 2 -3 weeks. The timing of starting open-label ganciclovir administration was similar for the two groups: day 43 for the ganciclovir plus IVIG group and day 44 for the IVIG alone group.
The survival rate was similar among both groups: 79% (23 of 29) among the ganciclovir plus IVIG group and 85% (23 of 27) among the IVIG group. The causes of death in the ganciclovir plus IVIG group were CMV disease (1 patient), liver failure (1 patient), lymphoproliferative disease (1 patient), multiorgan failure (2 patients), and sepsis (1 patient). The causes of death in the IVIG alone group were lymphoproliferative disease (1 patient) and multiorgan failure (3 patients). There were no deaths due to CMV disease in the IVIG alone after liver transplantation for children receiving ganciclovir plus intragroup. The one death classified as CMV-associated was due venous immune globulin (IVIG) (n Å 29) or placebo plus IVIG (n Å 27) as prophylaxis for cytomegalovirus disease.
to respiratory arrest on day 148 in a patient who had been / 9c3f$$no44 10-17-97 21:57:20 cida UC: CID NOTE. Acy Å acyclovir; CMV Å cytomegalovirus; CMVIG Å cytomegalovirus immune globulin; Gcv Å ganciclovir; IVIG Å intravenous immune globulin; NA Å not available; PR Å present report. the survival among these 11 patients treated with acyclovir for this improvement in outcome for the control group are as were not different from those for the whole study group.
follows: improvement in transplantation procedures not related to CMV disease, such as organ harvesting, surgical techniques, and treatment of bacterial and fungal infections; increased Discussion awareness of CMV disease, leading to earlier diagnosis and treatment; improved diagnostic tests for CMV disease, leading Prophylactic strategies for CMV disease have included use to earlier diagnosis; and the prophylactic effect of IVIG on of CMV-seronegative blood products, IVIG, high-dose CMV disease. It is probable that all of these explanations conacyclovir, and ganciclovir. Prospective, randomized, controlled tributed to the decrease in the incidence of CMV disease. trials evaluating these strategies have enrolled mostly adult Although this study is the largest (56 patients) reported rantransplant recipients, with only a few transplant recipients at domized trial of prophylaxis for CMV disease in CMV-serorisk for primary infection (CMV-seropositive donor/CMVnegative recipients of liver transplants from CMV-seropositive seronegative recipient) [10 -17] . None of these prophylactic donors, there was no statistically significant difference between strategies have been demonstrated to be consistently effective the ganciclovir plus IVIG group and the IVIG alone group. A in the prevention of primary CMV disease. The results from sample size of 350 patients per group would have been required these trials for CMV-seronegative recipients of transplants to confirm a difference of CMV disease of 9% with an a error from CMV-seropositive donors are shown in table 3. One of of 0.05 and a b error of 0.20. There was a trend toward later the lowest rates of primary CMV disease (10%) was reported onset of CMV disease in the ganciclovir plus IVIG group, thus with use of a long course of ganciclovir prophylaxis. However, suggesting that a longer duration of ganciclovir prophylaxis these results are based on a small number of CMV-seronegative might be more effective. This trend toward longer ganciclovir recipients of transplants from CMV-seropositive donors.
prophylaxis being more effective is supported by the results of To our knowledge, our study is the largest randomized trial two studies of ganciclovir prophylaxis, one for 100 days and of prophylaxis for CMV disease in CMV-seronegative recipithe other for 7 days, respectively [11, 14] . In the randomized, ents of liver transplants from CMV-seropositive donors ever controlled trial in which ganciclovir was given for 7 days [14] , reported. Since transplant recipients were recruited from six CMV disease occurred in 55% of CMV-seronegative recipients centers in North America, the results are likely to be generalizof transplants from CMV-seropositive donors who were in the able to other North American transplant programs. One of the ganciclovir group. However, in the randomized, controlled trial problems with this study is its length. During the study period in which ganciclovir was given for 100 days [11] , CMV disease (1991 -1994), many changes occurred that improved the outoccurred in 10% of CMV-seronegative recipients of transplants come for liver transplant recipients. On the basis of data before from CMV-seropositive donors who were in the ganciclovir 1990, the expected incidence of CMV disease among CMVgroup. seronegative recipients of liver transplants from CMV-seroposTo assess the effectiveness of this prophylactic strategy comitive donors was 60%, but in our study, the incidence was 26% among the IVIG alone (control) group. Possible explanations pared with that of others, the outcomes for CMV-seronegative / 9c3f$$no44 10-17-97 21:57:20 cida UC: CID recipients of liver transplants from CMV-seropositive donors negative recipients of transplants from CMV-seropositive donors who were in the control and ganciclovir groups, respecwho were from included in other prospective, randomized trials were reviewed (table 3) . A meta-analysis was not performed.
tively. The incidence of CMV disease in these groups was 44% and 3%, respectively. The use of oral ganciclovir as prophylaxis However, the data from these studies were pooled to show the results of the prophylactic strategies of acyclovir alone, for CMV disease is therefore a very attractive option. Further studies are needed to determine the optimal strategy ganciclovir alone (or with sequential acyclovir), IVIG alone, and the combination of ganciclovir and IVIG. The incidence for prophylaxis for CMV disease, especially in this high-risk group (CMV-seropositive donor/CMV-seronegative recipient). of CMV disease was as follows: patients who received acyclovir alone (n Å 24), 42%; those who received ganciclovir These studies should focus on the effectiveness of longer courses of ganciclovir, perhaps with initial intravenous adminalone or ganciclovir followed by acyclovir (n Å 23), 22%; those who received CMV immune globulin (CMVIG) or IVIG istration followed by oral administration. The role of IVIG in prophylaxis for CMV disease also must be reevaluated in this alone (n Å 46), 37%; and those who received the combination of ganciclovir and IVIG (n Å 29), 17%. These results suggest setting, since more-effective antiviral agents are now available. that prophylaxis with acyclovir alone or IVIG alone is less effective than that with ganciclovir or ganciclovir in combina-
